XYLOCARD

This brand name is authorized in Canada, France

Active ingredients

The drug XYLOCARD contains one active pharmaceutical ingredient (API):

1 Lidocaine UNII V13007Z41A - LIDOCAINE HYDROCHLORIDE

Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. Read about Lidocaine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
XYLOCARD Solution for injection	Health Products and Food Branch (CA)	MPI, CA: SPM

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C01BB01	Lidocaine	C Cardiovascular system → C01 Cardiac therapy → C01B Antiarrhythmics, class I and III → C01BB Antiarrhythmics, class Ib
Discover more medicines within C01BB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 00001937
Country: FR	Base de données publique des médicaments	Identifier(s): 61100093, 65528593